Citius Pharmaceuticals, Inc. (CTXR)

Market Cap	21.80M
Revenue (ttm)	n/a
Net Income (ttm)	-40.99M
Shares Out	18.47M
EPS (ttm)	-4.78
PE Ratio	n/a
Forward PE	1.30
Dividend	n/a
Ex-Dividend Date	n/a

Volume	262,873
Open	1.240
Previous Close	1.250
Day's Range	1.180 - 1.257
52-Week Range	0.650 - 5.950
Beta	1.51
Analysts	Buy
Price Target	6.00 (+408.48%)
Earnings Date	Dec 26, 2025

About CTXR

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial fo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: CTXR
• Website: https://citiuspharma.com

Analyst Forecast

According to 2 analysts, the average rating for CTXR stock is "Buy." The 12-month stock price target is $6.0, which is an increase of 408.48% from the latest price.

Price Target

$6.0

(408.48% upside)

Analyst Consensus: Buy